Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ESMO 2023

20 - 24 Oct 2023
Madrid, Spain
Videos
News
Updates on lung cancer from WCLC and ESMO 2023
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
31 Jan 2024
First-line chemotherapy with atezolizumab and bevacizumab significantly...
Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain
First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )
4 Dec 2023
Trial investigates multiparametric prognostic score in early HR+/HER2- breast...
Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany
Trial investigates multiparametric prognostic score in early HR+/HER2- breast cancer ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )
21 Nov 2023
ESMO 2023: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Nov 2023
Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine...
Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA
Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )
7 Nov 2023
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...
Prof Ignace Vergote - UZ Leuven, Leuven, Belgium
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )
7 Nov 2023
CAR-T therapy and impact to cancer patient outcomes and experience of treatment
Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen...
CAR-T therapy and impact to cancer patient outcomes and experience of treatment ( Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen, Switzerland )
7 Nov 2023
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in...
Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )
7 Nov 2023
2 year recurrence free survival benefit for resectable melanoma treated with...
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
2 Nov 2023
Innovative treatments for solid tumours – TTFields as a therapeutic modality
Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic...
Innovative treatments for solid tumours – TTFields as a therapeutic modality ( Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart )
2 Nov 2023
Atezolizumab with platinum-based CT and niraparib show no improvement in...
Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra...
Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )
31 Oct 2023
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )
27 Oct 2023
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...
Prof Gerard Zalcman - Université de Paris, Paris, France
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )
27 Oct 2023
Adjuvant radiotherapy has no benefit following radical prostatectomy
Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK
Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )
27 Oct 2023
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall...
Dr Neil Gross - MD Anderson Cancer Center, Houston, USA
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )
27 Oct 2023
Where do we stand with mCRPC?
Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike...
Where do we stand with mCRPC? ( Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike Schlurmann )
25 Oct 2023
PARPi combinations to treat patients with mCRPC
Prof Axel Merseburger, Prof Karim Fizazi, Prof Laura-Maria Krabbe and Prof...
PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Prof Karim Fizazi, Prof Laura-Maria Krabbe and Prof Gerhardt Attard )
25 Oct 2023
Selpercatinib benefit, with or without pembro, in first-line advanced RET...
Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong
Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC ( Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong )
23 Oct 2023
ESMO 2023: Latest updates in mRCC
Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane...
ESMO 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane Oudard )
23 Oct 2023
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced...
Dr Mary McCormack - University College Hospital, London, UK
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )
23 Oct 2023
Active surveillance for oesophageal cancer shows improved HRQoL compared to...
Dr Berend Van der Wilk - Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Active surveillance for oesophageal cancer shows improved HRQoL compared to standard surgery ( Dr Berend Van der Wilk - Erasmus MC Cancer Institute, Rotterdam, The Netherlands )
23 Oct 2023
Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS...
Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy
Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer  ( Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy )
23 Oct 2023
Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer
Dr Aditya Bardia - Mass General Cancer Center, Boston, USA
Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )
23 Oct 2023
The latest in NSCLC with common EGFR mutations
Dr Alfredo Addeo, Dr Antonio Passaro, Dr Alex Spira and Prof Amanda Tufman
The latest in NSCLC with common EGFR mutations ( Dr Alfredo Addeo, Dr Antonio Passaro, Dr Alex Spira and Prof Amanda Tufman )
23 Oct 2023
Adding nivolumab to neoadjuvant chemo improves response rate for high risk ER+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Adding nivolumab to neoadjuvant chemo improves response rate for high risk ER+ HER2− breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
22 Oct 2023
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced...
Prof Thomas Powles - Barts Cancer Centre, London, UK
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer ( Prof Thomas Powles - Barts Cancer Centre, London, UK )
22 Oct 2023
Belzutifan improves PFS, ORR in clear cell renal cell carcinoma
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Belzutifan improves PFS, ORR in clear cell renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
22 Oct 2023
Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC
Dr Michiel Van der Heijden - Netherlands Cancer Institute, Amsterdam...
Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC ( Dr Michiel Van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )
22 Oct 2023
Effects of short-term fasting on quality of life as an add-on option during...
Dr Daniela Koppold-Liebscher - Charité Universitätsmedizin Berlin, Berlin...
Effects of short-term fasting on quality of life as an add-on option during chemotherapy ( Dr Daniela Koppold-Liebscher - Charité Universitätsmedizin Berlin, Berlin, Germany )
22 Oct 2023
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
22 Oct 2023
Genomic testing: Awareness and effective communication between healthcare...
Prof Richard Simcock and Antonella Cardone
Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )
22 Oct 2023
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC
Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )
22 Oct 2023
A biomarker led approach to bladder cancer
Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...
A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )
22 Oct 2023
Durvalumab addition to chemo shows endometrial cancer benefit
Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston...
Durvalumab addition to chemo shows endometrial cancer benefit ( Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston, USA )
21 Oct 2023
Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC
Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA
Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )
21 Oct 2023
Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant...
Dr Julien Hadoux - Institut Gustave Roussy, Villejuif, France
Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer ( Dr Julien Hadoux - Institut Gustave Roussy, Villejuif, France )
21 Oct 2023
CheckMate-77T: Perioperative nivolumab benefit for NSCLC
Dr Tina Cascone - MD Anderson Cancer Center, Houston, USA
CheckMate-77T: Perioperative nivolumab benefit for NSCLC ( Dr Tina Cascone - MD Anderson Cancer Center, Houston, USA )
21 Oct 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation